Welcome to our dedicated page for Pacira Biosciences news (Ticker: PCRX), a resource for investors and traders seeking the latest updates and insights on Pacira Biosciences stock.
Overview
Pacira BioSciences Inc (NASDAQ: PCRX) is a specialty pharmaceutical company committed to revolutionizing pain management by offering innovative non-opioid therapies and regenerative health solutions. With a core focus on providing safe and effective alternatives for pain control, the company leverages its proprietary drug delivery platforms to address acute pain in surgical and chronic conditions. Its approach combines advanced pharmaceutical formulations with novel medical devices, ensuring that clinicians have access to effective treatment options that reduce reliance on opioids.
Core Technologies and Products
At the heart of Pacira's innovation is its unique product delivery technology, which encapsulates active compounds without altering their molecular structures. This platform enables controlled, extended release of medications, ensuring long-lasting efficacy. The company has successfully commercialized several non-opioid treatments:
- EXPAREL: A long-acting local anesthetic designed to provide postsurgical pain control through sustained drug release, thereby reducing the need for opioids.
- ZILRETTA: An extended-release intra-articular injection indicated for the management of osteoarthritis knee pain, offering patients prolonged relief.
- iovera®: A handheld, drug-free device that applies controlled doses of cold therapy to targeted nerves, providing immediate and lasting pain relief.
In addition to these commercial products, Pacira is advancing its pipeline with a novel gene therapy candidate, PCRX-201. This locally administered therapy aims to treat osteoarthritis by regulating inflammatory pathways, thus addressing the root causes of pain and disability.
Market Position and Business Model
Pacira BioSciences operates at the intersection of innovative drug delivery and non-opioid pain management solutions. Its business model emphasizes:
- Commercialization of Proven Therapies: The company has established a presence in markets requiring effective postsurgical and chronic pain management solutions, evidenced by the wide adoption of its therapies in diverse clinical settings.
- Advanced R&D and Pipeline Development: By investing in robust research and development programs, along with strategic partnerships, Pacira continues to expand its portfolio and maintain competitive differentiation in the specialty pharmaceutical sector.
- Regulatory and Reimbursement Strategies: With products that have secured critical reimbursement designations, Pacira enhances market access for its non-opioid therapies across different healthcare settings. This strategic emphasis supports clinician adoption and broader patient access.
Clinical and Commercial Significance
The company's focus on non-opioid pain management comes at a time when reducing opioid dependency is an urgent priority in healthcare. By developing treatments that not only manage pain effectively but also minimize opioid consumption, Pacira is addressing a key public health challenge. Its clinically validated products have been incorporated into pain management protocols in hospitals and outpatient settings alike, offering enduring benefits for patients and healthcare providers.
Innovative Edge and Future Pipeline
Pacira’s utilization of advanced drug delivery systems, such as multivesicular liposomes and precise cryoneurolysis, underscores its commitment to innovation. These technologies not only improve therapeutic outcomes but also facilitate streamlined billing and regulatory approval processes through established coding systems. With an evolving pipeline that includes gene therapy approaches, the company is poised to expand its reach into additional therapeutic areas, addressing unmet needs in the treatment of chronic and musculoskeletal pain.
Competitive Landscape and Differentiators
In a competitive market, Pacira differentiates itself through its deep expertise in non-opioid pain management and its commitment to technological advancements. The integration of robust clinical data, strategic reimbursement initiatives, and a focus on delivering sustained therapeutic benefits positions the company as a trusted innovator among healthcare practitioners. Unlike traditional pain management solutions that rely heavily on opioids, Pacira’s products are designed to provide effective relief with reduced risk of dependency, offering a clinically superior alternative in the evolving landscape of pain management.
Conclusion
With a comprehensive portfolio that spans commercial-stage products and a promising pipeline, Pacira BioSciences Inc stands as a key player in the specialty pharmaceutical industry. Its ongoing commitment to developing non-opioid pain therapies, underpinned by advanced drug delivery technologies and rigorous clinical validation, ensures that it remains an authoritative source of innovation and expertise in pain management and regenerative health.
Pacira BioSciences (PCRX) has granted inducement awards to six new employees on March 4, 2025, under its Amended and Restated 2014 Inducement Plan. The awards include:
- Stock options for 23,500 shares granted to five employees, with a 10-year term and exercise price of $23.53 per share
- 29,400 restricted stock units (RSUs) distributed among six employees
The stock options follow a four-year vesting schedule with 25% vesting on first employment anniversary and quarterly installments over 36 months thereafter. RSUs vest annually in four equal installments starting March 1, 2026. All awards require continued employment and were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
Pacira BioSciences (PCRX) reported its Q4 and full-year 2024 financial results, achieving record revenues of $701 million for the year, a 4% increase from 2023. The company posted a full-year GAAP net loss of $99.6 million and adjusted EBITDA of $223.9 million.
Key Q4 metrics include revenues of $187.3 million and GAAP net income of $16 million. Product performance showed EXPAREL sales at $147.7 million (+3%), ZILRETTA at $33.1 million (+15%), and iovera° at $6.5 million (+7%).
The company announced its new Five-Year Plan (5x30) to transition into an innovative biopharmaceutical organization, focusing on musculoskeletal pain. Strategic moves include acquiring the remaining 81% stake in GQ Bio for $32 million and receiving FDA clearance for a new iovera° SmartTip for chronic low back pain management.
For 2025, Pacira projects total revenue between $725-765 million, with non-GAAP gross margins of 76-78%.
Pacira BioSciences (PCRX) has acquired the remaining 81% equity stake in GQ Bio Therapeutics for approximately $32 million. The transaction includes $18 million paid at closing, $8 million over three years for key employee retention, and a $6 million post-closing indemnity holdback.
The acquisition strengthens Pacira's '5x30' strategy to become an innovative biopharmaceutical organization, adding GQ Bio's high-capacity adenovirus (HCAd) gene therapy vector platform. This platform enables efficient genetic medicines delivery and supports multiple gene constructs, particularly focusing on musculoskeletal diseases.
The deal eliminates Pacira's future milestone payment obligations of up to $64 million, including a $4.5 million payment due for PCRX-201's Phase 2 clinical trial initiation. Pacira plans to maintain GQ Bio's operations and invest in the HCAd platform, leveraging its clinical, regulatory, and commercial capabilities to address chronic pain conditions affecting nearly 1 in 4 Americans.
Pacira BioSciences (Nasdaq: PCRX), a leader in non-opioid pain therapies, has announced its participation in two major healthcare conferences in March 2025. The company will engage in analyst-led fireside chats at:
- The Raymond James 46th Annual Institutional Investors Conference on March 5th at 10:25AM ET
- The Barclays 27th Annual Global Healthcare Conference on March 12th at 8:00AM ET
Both events will be accessible via live audio on the company's website investor.pacira.com under the 'Events' section. Webcasts will remain available for replay for two weeks following each event.
Pacira BioSciences (PCRX) has announced it will release its fourth quarter and full-year 2024 financial results after U.S. markets close on Thursday, February 27, 2025. The company will host a conference call and webcast at 4:30 p.m. ET on the same day.
Interested participants can pre-register for the Q&A session via telephone, and all registrants will receive dial-in information and a PIN for call access. The conference call will also be available as a webcast through the 'Events' page on Pacira's investor website. A replay of the webcast will be accessible on the company's website for approximately two weeks following the call.
Pacira BioSciences (PCRX) announced inducement grants to 15 new employees on February 4, 2025, under its Amended and Restated 2014 Inducement Plan. The grants include significant awards to two key executive appointments: Brendan Teehan as Chief Commercial Officer and Krys Corbett as Chief Business Officer.
Teehan received options to purchase 99,500 shares at $26.59 per share and 54,000 restricted stock units (RSUs). Corbett received options for 88,400 shares at $26.59 and 46,000 RSUs. Additionally, four employees received options to purchase 20,600 shares, and 13 employees received 45,400 RSUs.
The stock options have a 10-year term with four-year vesting schedules. RSUs vest in four equal annual installments starting February 1, 2026. All awards are subject to continued employment with Pacira.
Pacira BioSciences (PCRX) announced significant changes to its Board of Directors. Laura Brege has been appointed as Chair of the Board, while former Chair Paul J. Hastings and Andreas Wicki have retired. The Board now consists of nine directors, with eight being independent and five joining since October 2023.
Brege brings over a decade of experience with Pacira and 30 years of executive management expertise in the pharmaceutical and biotechnology industries. She has held executive positions at BridgeBio Pharma, Onyx Pharmaceuticals, and COR Therapeutics.
These changes are part of Pacira's ongoing Board transformation, which began 15 months ago with the appointment of four new independent directors. Additionally, Alethia Young has been appointed as the new Chair of the Audit Committee, succeeding Brege in this role.
Pacira BioSciences (NASDAQ: PCRX) has announced two key appointments to its executive leadership team as part of its '5x30' strategy to become an innovative biopharmaceutical organization. Brendan Teehan has been appointed as Chief Commercial Officer, bringing 30 years of experience in building commercial teams across multiple therapeutic categories. Previously, he served as Chief Operating Officer at Acadia Pharmaceuticals.
Krys Corbett joins as Chief Business Officer, contributing over 25 years of experience in business development and strategic transactions. She previously led portfolio and product strategy at Lyell Immunopharma and served as Head of Business Development at Oric Pharmaceuticals.
These appointments are intended to enhance the company's execution of its growth strategy, combining Teehan's expertise in maximizing pharmaceutical brands with Corbett's portfolio management and partnering experience.
Pacira BioSciences (PCRX) announced its five-year strategic plan '5x30' alongside preliminary unaudited 2024 revenue of $701.0 million, up from $675.0 million in 2023. The 5x30 plan aims to achieve five key objectives by 2030, including treating over three million patients annually, achieving double-digit revenue growth, improving gross margin by five percentage points, expanding clinical pipeline with five novel programs, and establishing five partnerships.
Key 2024 revenue highlights include EXPAREL net product sales of $549.0 million (up from $538.1 million in 2023), ZILRETTA sales of $118.1 million (up from $111.1 million), and iovera° sales of $22.8 million (up from $19.7 million). Fourth quarter EXPAREL sales reached $147.7 million, with growth driven by volume increases and pricing, partially offset by vial mix shifts and GPO partnership discounts.
Pacira BioSciences (Nasdaq: PCRX) has received FDA 510(k) clearance for a new Smart Tip designed for the iovera° system to manage chronic low back pain via long-lasting medial branch nerve block. The iovera° system uses cryoneurolysis, applying focused cold therapy to nerves to interrupt pain signals temporarily. The new 25-gauge, 180-mm Smart Tip treats deeper nerves, including the medial branch nerve, and is designed to relieve chronic low back pain associated with facet-mediated pain.
Chronic low back pain is a significant health issue in the U.S., leading to disability and opioid prescriptions. The iovera° system provides an alternative to radiofrequency ablation (RFA), which has limitations like delayed pain relief and potential tissue damage. A single-center randomized pilot study showed that patients treated with iovera° reported pain scores more than 2 points lower at 180 and 360 days compared to RFA-treated patients. Additionally, iovera° patients exhibited significant functional improvements and greater satisfaction with pain management.
The FDA clearance of this new Smart Tip is a step forward in offering drug-free, effective pain relief for millions of Americans with chronic back pain.
FAQ
What is the current stock price of Pacira Biosciences (PCRX)?
What is the market cap of Pacira Biosciences (PCRX)?
What is the core focus of Pacira BioSciences Inc?
How does Pacira differentiate its products in the market?
What are the key commercial-stage products offered by Pacira?
What technology underpins Pacira's drug delivery system?
How does Pacira address the issue of opioid dependency?
What is PCRX-201 and what potential does it hold?
Which healthcare settings benefit from Pacira's therapies?
What role do reimbursement strategies play in Pacira's business model?
How does Pacira support clinical decision-making and patient care?
